Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Covelli

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
ESMO Open|November 16, 2024
Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patientsS Genta, D V Araujo, K Hueniken, et al.
Leukemia|March 19, 2015
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European CountriesV S Hoffmann, M Baccarani, J Hasford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2025
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanomaK C Kähler, J C Hassel, M Ziemer, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
ESMO Open|November 16, 2024
Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patientsS Genta, D V Araujo, K Hueniken, et al.
Leukemia|March 19, 2015
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European CountriesV S Hoffmann, M Baccarani, J Hasford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2025
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanomaK C Kähler, J C Hassel, M Ziemer, et al.
Pageof 3